Abstract
Boston Scientific has announced the launch of its new CHARGER™ PTA Balloon catheter in USA in the same week that it has gained FDA approval for what the company claims is the World’s first and only 16-contact percutaneous lead for treatment of patients suffering chronic pain.
New PTA Balloon Catheter
CHARGER™ is a 0.035″ percutaneous transluminal angioplasty (PTA) balloon catheter designed for a wide range of peripheral angioplasty procedures. It is compatible with a 6 Fr sheath for 10×80 mm balloons and is available in a broad range of sizes including 3-12 mm diameters and 20-200 mm lengths on 75 or 135 cm shafts. The product represents Boston Scientific’s third new peripheral balloon catheter introduced in 2011 and strengthens the Company’s position as a global leader in peripheral angioplasty balloons although at the present time it is not available outside USA.
Company comments
According to Jeff Mirviss, President of Boston Scientific’s Peripheral Interventions Division; “The Charger PTA Balloon Catheter is designed to deliver results in both routine and challenging cases. With a low profile and tapered tip, it is engineered to provide excellent push without sacrificing track. The Charger PTA Balloon Catheter complements our growing portfolio of interventional devices for peripheral vasculature procedures.”
Infinion™ 16 Percutaneous Lead for Precision Plus™ Spinal Cord Stimulator System
Spinal Cord Stimulator (SCS) leads are designed to deliver electrical pulses from an implantable pulse generator to the spinal cord to mask pain signals to the brain. Previous percutaneous leads have offered a maximum of eight stimulating contacts, which is now doubled to 16 with the introduction of this product, offering more coverage of the spinal cord for the management of chronic pain. (Photo courtesy PR Newswire)
Company comments
“The Infinion 16 Lead is the latest advance in lead technology and an exciting new addition to our unrivaled percutaneous lead portfolio,” stated Maulik Nanavaty, Senior Vice President and President of Boston Scientific’s Neuromodulation Division. “With the launch of the Infinion 16 Lead, Boston Scientific continues its commitment to innovation by offering pain management physicians more choices to help optimize pain relief for their patients.”
Source: Boston Scientific
published: December 12, 2011 in: Approval/Clearance, Boston Scientific, Cardio, Launches / Withdrawals, Regulatory, Spine, Vascular